Tekmira Acquires License to Novel RNAi Technology for Therapeutic Development | GenomeWeb

Tekmira Pharmaceuticals said this week that it has acquired an exclusive, worldwide license to an RNAi technology developed by Halo-Bio RNAi Therapeutics.

The technology, called multivalent RNAi, comprises “single macromolecules capable of mediating RNAi at multiple unique target sites,” Tekmira said. “MV-RNA can target three sites on a single gene or up to three separate genes simultaneously.”

Tekmira said that it aims to combine the molecules with its proprietary lipid nanoparticles to develop therapeutics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.